PREEMPTIVE THERAPY VERSUS UNIVERSAL PROPHYLAXIS WITH VALGANCICLOVIR IN MINIMIZING THE RISK OF CYTOMEGALOVIRUS DISEASE IN KIDNEY TRANSPLANT RECIPIENTS

被引：0
作者：
Khan, Muhammad [1 ]
机构：
[1] DOW Univ Hosp, Karachi, Pakistan
来源：
TRANSPLANT INTERNATIONAL | 2019年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
MP077
引用
收藏
页码：295 / 295
页数：1
相关论文
共 50 条
  • [41] Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients A Randomized Clinical Trial
    Limaye, Ajit P.
    Budde, Klemens
    Humar, Atul
    Vincenti, Flavio
    Kuypers, Dirk R. J.
    Carroll, Robert P.
    Stauffer, Nicole
    Murata, Yoshihiko
    Strizki, Julie M.
    Teal, Valerie L.
    Gilbert, Christopher L.
    Haber, Barbara A.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 330 (01): : 33 - 42
  • [42] Universal Prophylaxis for Cytomegalovirus Disease in Pediatric Liver Transplant Recipients
    Gautier, S.
    Tsirulnikova, O.
    Zhilkin, I.
    Akhaladze, D.
    Tsirulnikova, I.
    Chekletsova, E.
    TRANSPLANTATION, 2016, 100 : S202 - S202
  • [43] The Cost-effectiveness of Valganciclovir Prophylaxis Versus Preemptive Therapy in CMV R+ Kidney Transplant Recipients Over the First Year Posttransplantation
    Villeneuve, Claire
    Rerolle, Jean-Phillipe
    Couzi, Lionel
    Westeel, Pierre-Francois
    Etienne, Isabelle
    Esposito, Laure
    Kamar, Nassim
    Buchler, Mathias
    Thierry, Antoine
    Marquet, Pierre
    Monchaud, Caroline
    TRANSPLANTATION DIRECT, 2024, 10 (08):
  • [44] Prophylaxis Versus Preemptive Therapy for Prevention of the Consequences of Cytomegalovirus Infection in Transplant Recipients: A Still Unresolved Issue
    Potena, Luciano
    Grigioni, Francesco
    Magnani, Gaia
    Branzi, Angelo
    TRANSPLANTATION, 2009, 87 (02) : 305 - 306
  • [45] Oral Valganciclovir As Preemptive Therapy for Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients
    Ozkocaman, Vildan
    Ozkalemkas, Fahir
    Ali, Ridvan
    Karacan, Yasemin
    Ersal, Tuba
    Gozden, Hilmi Erdem
    Erus, Tugcan
    Kazak, Esra
    Akalin, Halis
    BLOOD, 2014, 124 (21)
  • [46] Impact of Valganciclovir Prophylaxis Dosing in High Risk Cytomegalovirus Kidney and Pancreas Transplant Recipients with Delayed Graft Function
    Gharabagi, A.
    Geyston, J.
    Agarwal, A.
    Rao, S.
    Doyle, A.
    Dann, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 : 607 - 607
  • [47] A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients
    Humar, A
    Kumar, D
    Preiksaitis, J
    Boivin, G
    Siegal, D
    Fenton, J
    Jackson, K
    Nia, S
    Lien, D
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (06) : 1462 - 1468
  • [48] A study of the Incidence of Cytomegalovirus Infection and Preemptive Therapy in Kidney Transplant Recipients
    Saleem, Zana Sidiq M.
    Abd, Kais H.
    Ibrahim, Nashwan M. R.
    Hussein, Nawfal R.
    Al-Khammas, Hasanain Ma
    JOURNAL OF CONTEMPORARY MEDICAL SCIENCES, 2022, 8 (01): : 44 - 46
  • [49] Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial
    不详
    TRANSPLANTATION, 2023, 107 (12) : 2448 - 2448
  • [50] Extended Valganciclovir Prophylaxis Does Not Prevent Late-Onset Cytomegalovirus Disease in Kidney Transplant Recipients.
    Kalpoe, Jayant S.
    Sehgal, Vinita
    Bindal, Sapan
    Huprikar, Shirish
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : 550 - 551
12345